FDA grants Orphan Drug Designation to Dewpoint Therapeutics’ DPTX3186 for the treatment of gastric cancer
Thursday, October 30, 2025
Dewpoint Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to DPTX3186, its first-in-class condensate modulator developed for the treatment of gastric cancer. The designation follows the company’s recent approval of its Investigational New Drug (IND) application for DPTX3186, marking Dewpoint’s transition into a clinical-stage biotechnology company and the beginning of the first human study involving a condensate-modulating therapy.
The FDA’s Orphan Drug Designation programme supports the development of treatments for rare diseases affecting fewer than 200,000 people in the United States. It provides several incentives, including seven years of market exclusivity upon approval, FDA fee waivers, tax credits for clinical trials, and eligibility for enhanced regulatory assistance and expedited review.
DPTX3186 is an oral small-molecule condensate modulator designed to target oncogenic Wnt/β-catenin signalling by redistributing β-catenin into an inactive condensate state within tumour cells. This approach aims to address safety challenges that have limited previous Wnt inhibition strategies. The programme also includes a condensate-based biomarker component to measure pharmacodynamic effects in patient samples.
Dewpoint plans to begin dosing the first patient with DPTX3186 by the end of 2025 at leading cancer centres across the United States.
Source: globenewswire.com
